The present invention relates to the use of human herpesvirus 6 (HHV-6) U94 gene and its product, the protein Rep, in human therapy, According to the invention, the protein Rep or the Rep-coding HHV-6 U94 gene are delivered to human blood and lymphatic endothelial cells, whereby angiogenic and lymphoangiogenic processes are inhibited. The invention further provides expression vectors and pharmaceutical compositions suitable for the delivery of the U94 gene or the protein encoded therefrom to thetherapeutic sites.
Anti-(lympho)angiogenic compositions and therapeutic applications thereof
DI LUCA, Dario
2008
Abstract
The present invention relates to the use of human herpesvirus 6 (HHV-6) U94 gene and its product, the protein Rep, in human therapy, According to the invention, the protein Rep or the Rep-coding HHV-6 U94 gene are delivered to human blood and lymphatic endothelial cells, whereby angiogenic and lymphoangiogenic processes are inhibited. The invention further provides expression vectors and pharmaceutical compositions suitable for the delivery of the U94 gene or the protein encoded therefrom to thetherapeutic sites.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
